Articles from Xilio Therapeutics, Inc.

WALTHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2025, the company granted non-qualified stock options to purchase an aggregate of 22,900 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50 am EST.

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments

WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective February 1, 2025, the company granted non-qualified stock options to purchase an aggregate of 83,400 shares of its common stock to four new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases

WALTHAM, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective January 1, 2025, the company granted a non-qualified stock option to purchase 60,000 shares of its common stock to one new employee under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective January 1, 2025, the company granted a non-qualified stock option to purchase 375,000 shares of its common stock to Caroline Hensley, its newly hired Chief Legal Officer, under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities

WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer.

WALTHAM, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective December 1, 2024, the company granted non-qualified stock options to purchase 8,400 shares of its common stock to one new employee under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with difficult-to-treat, immunologically “cold” tumors

Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-breaker poster presentation at the SITC Annual Meeting

WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that initial data from its Phase 1C dose escalation of XTX101 (vilastobart) in combination with atezolizumab in patients with advanced solid tumors will be presented in a late-breaker poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024.

WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024. The company plans to present preclinical data from its tumor-activated SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) format.

WALTHAM, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2024, the Compensation Committee of the Board of Directors granted non-qualified stock options to purchase an aggregate of 101,000 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

WALTHAM, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, at 7:00 am EDT.

Initiated enrollment in Phase 2 clinical trial of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC)

WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company’s board of directors.

Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024

On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024

Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and leveraging the company’s promising research platform for tumor-activated bispecific and cell engager molecules

WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in the “Novel Immuno-Oncology” panel discussion during the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 10:30 am EST.

WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 pm EST.

Dosing XTX301 at 45 ug/kg once every three weeks (dose level 3) in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no dose-limiting toxicities observed to date

Phase 1 combination dose escalation expected to support planned Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC)

Demonstrated initial clinical validation of tumor-selective activation technology for both XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and XTX202, a tumor-activated, beta-gamma IL-2

Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8 mg/kg) and 31% disease control rate across all dose levels in a range of solid tumor types, including cold tumors

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, which will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023.

WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023. The company plans to present preliminary anti-tumor activity, safety, pharmacokinetic and pharmacodynamic data from its Phase 1/2 clinical trial for XTX202, a tumor-activated, engineered, beta-gamma biased IL-2, as well as preclinical data for XTX301, a tumor-activated, engineered IL-12.

Martin Huber, M.D., to leave Xilio Therapeutics and remain an advisor

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 2:55 pm EST.

Xilio entered into clinical trial collaboration with Roche to evaluate XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq®), in patients with microsatellite stable (MSS) colorectal cancer

WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the promotion of Chris Frankenfield to chief operating officer of Xilio.

Encouraging preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell lung cancer

Initiated Phase 2 clinical trial for XTX202, a tumor-activated IL-2

WALTHAM, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the Compensation Committee of the Board of Directors granted a non-qualified stock option to purchase 55,000 shares of common stock to Kevin Brennan, the company’s newly hired Senior Vice President, Finance and Accounting. The stock option was granted effective as of April 1, 2023 under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as an inducement material to Mr. Brennan entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

Initial clinical data from XTX101, XTX202 and XTX301 clinical trials anticipated in 2023

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced its participation in the following upcoming investor conferences:

WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in Citi’s 2023 Virtual Oncology Leadership Summit on Thursday, February 23, 2023, at 9:00 a.m. ET.

WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023, at 3:55 p.m. ET in New York.

WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will host a live virtual program on Thursday, December 1, 2022, at 12:30 p.m. ET spotlighting Xilio’s clinical-stage molecule XTX301, a tumor-activated, engineered IL-12.

XTX202, a tumor-activated IL‑2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with no signs of vascular leak syndrome

WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will participate in a virtual fireside chat at the Cowen 6th Annual IO Next Summit on Friday, November 11, 2022, at 1:40 p.m. ET.

Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced the pricing of its initial public offering of 7,353,000 shares of its common stock at a price to the public of $16.00 per share. The gross proceeds to Xilio from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Xilio, are expected to be approximately $117.6 million. In addition, Xilio has granted the underwriters a 30-day option to purchase up to an additional 1,102,950 shares of its common stock at the initial public offering price less underwriting discounts and commissions. All of the shares are being offered by Xilio.

Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate XTX202, its tumor-selective IL-2 product candidate, as a potential treatment for patients with solid tumors. XTX202 is designed to localize activity in the tumor microenvironment (TME), with the goal of overcoming the known tolerability challenges of existing IL-2 therapies while achieving enhanced anti-tumor activity.

Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced that Timothy D. Hunt has been appointed as the company’s chief culture and corporate affairs officer. In this role, Mr. Hunt will serve as a member of the executive team and will oversee human resources, communications and other strategic initiatives.

Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced that the first patient has been dosed in the company’s Phase 1/2 clinical trial evaluating XTX101 for the treatment of solid tumors. XTX101 is a tumor-selective anti-CTLA-4 monoclonal antibody designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies by overcoming their historical potency and tolerability limitations.

Xilio Therapeutics, Inc. (Xilio), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of biotech executive Sara Bonstein, chief financial officer of Insmed, Inc. (Insmed), to Xilio’s board of directors.